{"id":"W4281769949","doi":"10.1200/jco.2022.40.16_suppl.2500","title":"Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre; Royal Victoria Regional Health Centre; Université Laval; Princess Margaret Cancer Centre; Royal Victoria Hospital; University of Toronto; University Health Network","funders":"","keywords":"Pembrolizumab; Medicine; Melanoma; Toxicity; Internal medicine; Combination therapy; Renal cell carcinoma; Interleukin 2; Nivolumab; Oncology; CD8; Pharmacology; Cytokine; Immunotherapy; Cancer research; Cancer; Immunology; Immune system","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006057367,0.0005673433,0.0008180447,0.0002558559,0.0002364765,0.0005997902,0.0004199444,0.0005846569,0.002475789],"category_scores_gemma":[0.00043186,0.0002867879,0.000668688,0.0002975971,0.0003557941,0.0004089105,0.0002651059,0.001205492,0.0006742934],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007758182,"about_ca_system_score_gemma":0.0007630003,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007832343,"about_ca_topic_score_gemma":0.00231133,"domain_scores_codex":[0.999819,0.00006932309,0.00001414455,0.00003732168,0.00002440353,0.00003581993],"domain_scores_gemma":[0.9997795,0.00003486431,0.00003902979,0.00001340814,0.00001170538,0.0001215937],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.58177,0.0326615,0.04426592,0.001779256,0.00183439,0.0007623013,0.0004944822,0.003142783,0.06457483,0.0003377947,0.00986474,0.258512],"study_design_scores_gemma":[0.2943753,0.5382353,0.1306073,0.0002221424,0.001651865,0.001941498,0.0002169257,0.002258649,0.009371636,0.000245561,0.02080913,0.00006471141],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9895585,0.005968241,0.0001734534,0.0003651938,0.0000707318,0.0004981051,0.0007723378,0.00003446161,0.002558884],"genre_scores_gemma":[0.9936116,0.00235387,0.0004468781,0.0004561646,0.00009657176,0.0002823943,0.001389826,0.000007784184,0.001354865],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002475789,"threshold_uncertainty_score":0.008282363,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03239957015714685,"score_gpt":0.3873364071985071,"score_spread":0.3549368370413603,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}